Guggenheim raised the firm’s price target on Jade Biosciences (JBIO) to $32 from $23 and keeps a Buy rating on the shares. Following the Q1 update, the firm is revising its detailed IgAN market model, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences: Buy Rating Reiterated on Strong Cash Runway, JADE101 Differentiation, and Unchanged $24 Price Target
- Analyst Reiterates Buy on Jade Biosciences as JADE101 Data and Multi-Asset Pipeline Catalysts Approach
- Jade Biosciences files $600M mixed securities shelf
- Jade Biosciences files to sell 39.54M shares of common stock for holders
- Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright